Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast mark...
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) ap...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by whic...
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4...
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with ...
World's Largest Psychedelics Conference Boasts 12K Attendees
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and ye...
Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K.
